Incyte (INCY) PT Raised to $121 at BMO Capital on Higher Probability of Epacadostat+Keytruda Sucecss

October 7, 2016 11:08 AM EDT
Get Alerts INCY Hot Sheet
Price: $87.72 -0.87%

Rating Summary:
    21 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade INCY Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

BMO Capital analyst M. Ian Somaiya reiterated an Outperform rating and raised his price target on Incyte (NASDAQ: INCY) to $121 (from $100) to reflect higher probability of success (80% vs. prior 50%) of epacadostat+Keytruda in melanoma given PFS strength (>12 months vs. Opdivo+Yervoy 11.5) observed in updated P1 data presented at the European Society for Medical Oncology meeting.

The firm also raised their baricitinib sales estimates to reflect continued positive feedback from rheumatologists and our expectation for a discounted pricing strategy that should drive adoption. The next key catalyst is decision by YE16 to advance epacadostat into P3 trials in other tumor histologies.

For an analyst ratings summary and ratings history on Incyte click here. For more ratings news on Incyte click here.

Shares of Incyte closed at $94.78 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

BMO Capital

Add Your Comment